Clinical Trial Update: Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD [Phase 2]

View source ↗

Summary

Phase 2 trial update on pulsed inhaled nitric oxide for WHO Group 3 pulmonary hypertension associated with COPD has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Pulmonary Hypertension

Drugs mentioned

• pulsed inhaled nitric oxide (nitric oxide)

Snippet

Sponsor: Bellerophon Pulse Technologies | Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED